Loading
Three trials reported together in 2005 showed that a year of trastuzumab after surgery cuts the risk of dying from HER2-positive breast cancer by about a third.
HERA, NSABP B-31 and NCCTG N9831, led by trial NCT00045032 and sponsored by BIG, NSABP and NCCTG, were three adjuvant trials reported together in 2005 that showed a year of trastuzumab after surgery cuts the risk of dying from HER2-positive breast cancer by about a third. Across roughly 9,000 women the joint B-31 and N9831 analysis and the HERA trial both showed large, durable improvements in disease-free and overall survival at ten and eleven years despite heavy crossover in HERA, turning the worst breast cancer subtype into one of the most curable, and HERA also showed that two years of trastuzumab is no better than one. OnCo links them to HER2 as a target, trastuzumab, Barbara Bradfield, Norman Wolmark, Charles E. Geyer Jr., David Cameron, Martine Piccart and the NSABP Foundation. Whether shorter courses can match a year, as PERSEPHONE later asked, is the question that followed.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
9,000 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| 10-year overall survival (B-31/N9831) | Chemotherapy + trastuzumab | 2,028 | 84% | 0.63 (0.54 to 0.73) | - | link |
| Chemotherapy alone | 2,018 | 75.2% | ||||
| Disease-free survival (B-31/N9831)primary | Chemotherapy + trastuzumab | - | - | 0.6 (0.53 to 0.68) | - | link |
| Chemotherapy alone | - | - |
A second publication from the HERA trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
This is the paper Europe PMC returns for registry id NCT00045032 with the most citations, so it is the natural first reading for anyone following the HERA trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
Shares Charles E. Geyer Jr., NSABP Foundation, Early HER2-positive breast cancer, Trastuzumab.
Shares David Cameron, Early HER2-positive breast cancer, Trastuzumab, HER2-positive breast cancer.
Shares Early HER2-positive breast cancer, Trastuzumab, HER2-positive breast cancer, Monoclonal antibodies.
Shares David Cameron, Martine Piccart, Trastuzumab, HER2-positive breast cancer.
Shares Early HER2-positive breast cancer, Trastuzumab, HER2-positive breast cancer, Monoclonal antibodies.
Shares Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, Trastuzumab, HER2-positive breast cancer.
Shares Barbara Bradfield, Trastuzumab, HER2, HER2-positive breast cancer.
Shares Trastuzumab, HER2, HER2-positive breast cancer, Monoclonal antibodies.